PTGS2-899G > C and prostate cancer risk: A population-based nested case-control study (ProtecT) and a systematic review with meta-analysis

Prostate Cancer and Prostatic Diseases

Volumn 12, Issue 3, 2009, Pages 296-300

  Murad, A ^a   Lewis, S J ^a   Smith, G Davey ^a   Collin, S M ^a   Chen, L ^a   Hamdy, F C ^b   Neal, D E ^c   Donovan, J ^a   Martin, R M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTAGLANDIN E SYNTHASE; PROSTAGLANDIN ENDOPEROXIDASE SYNTHASE 2; UNCLASSIFIED DRUG;

CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CLINICAL TRIAL; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW;

AGED; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS;

EID: 70249084836     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2009.18     Document Type: Review

References (26)

1. Rowan S, Rachet B, Alexe DM, Cooper N, Coleman MP. Survival from prostate cancer in England and Wales up to 2001. Br J Cancer 2008; 99: S75-S77.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003; 91: 789-794.
4. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Eng J Med 2000; 343: 78-85.
5. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7 256-269.
6. Hussain T, Gupta S, Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 2003; 191: 125-135.
7. Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Härkönen P. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res 2001; 29: 25-28.
8. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000; 42: 73-78.
9. Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000; 89: 589-596.
10. Lee LM, Pan CC, Cheng CJ, Chi CW, Liu TY. Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res 2001; 21: 1291-1294.
11. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: Systematic review and meta-analysis. Br J Cancer 2004; 90: 93-99.
12. Panguluri RCK, Long LO, Chen W, Wang S, Coulibaly A, Ukoli F et al COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 2004; 25: 961-966.
13. Schmedtje Jr JF, Ji YS, Liu WL, DuBois RN, Runge MS. Hypoxia induces cyclooxygenase-2 via the NF-kappa B p65 transcription factor in human vascular endothelial cells. J Biol Chem 1997; 272: 601-608.
14. Lukiw WJ, Bazan NG. Strong nuclear factor-B-DNA binding parallels cyclooxygenase-2 gene transcription in aging and in sporadic Alzheimer's disease superior temporal lobe neocortex. J Neurosci Res 1998; 53: 583-592.
15. Charalambous MP, Maihöfner C, Bhambra U, Lightfoot T, Gooderham NJ, Colorectal Cancer Study Group. Upregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-kappa B and I kappa B kinase-alpha in human colorectal cancer epithelial cells. Br J Cancer 2003; 88: 1598-1604.
16. Ding J, Wu K, Zhang D, Luo W, Li J, Ouyang W et al. Activation of both nuclear factor of activated T cells and inhibitor of nuclear factor-kappa B kinase beta-subunit-nuclear factor-kappa B is critical for cyclooxygenase-2 induction by benzo [a] pyrene in human bronchial epithelial cells. Cancer Sci 2007; 98: 1323-1329.
17. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE et al. Common promoter variant in cyclooxygenase-2 represses gene expression evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002; 22: 1631-1636.
18. Brosens LAA, Iacobuzio-Donahue CA, Keller JJ, Hustinx SR, Carvalho R, Morsink FH. Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G → C COX-2 polymorphism. Clin Cancer Res 2005; 11 4090-4096.
19. Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD et al. PTGS2 (COX-2)-765G4 C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal antiinflammatory drugs. Cancer Epidemiol Biomarkers Prev 2005; 14: 616-619.
20. Avery KNL, Blazeby JM, Lane JA, Neal DE, Hamdy FC, Donovan JL. Decision-making about PSA testing and prostate biopsies: A qualitative study embedded in a primary care randomised trial. Eur Urol 2008; 53: 1186-1193.
21. Donovan J, Hamdy F, Neal D, Peters T, Oliver S, Brindle L et al. Prostate testing for cancer and treatment (ProtecT) feasibility study. Health Technol Assess 2003; 7: 1-88.
22. Zuccolo L, Harris R, Gunnell D, Oliver S, Lane JA, Davis M et al. Height and prostate cancer risk: A large nested case-control study (ProtecT) and meta-analysis. Cancer Epidemiol Biomarkers Prev 2008; 17: 2325-2336.
23. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professional's follow-up study. Int J Cancer 2007; 121: 1571.
24. Kristal AR, Stanford JL. Cruciferous vegetables and prostate cancer risk confounding by PSA screening. Cancer Epidemiol Biomarkers Prev 2004; 13: 1265.
25. Cheng I, Liu X, Plummer S, Krumroy L, Casey G, Witte J. COX-2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer 2006; 97: 557-561.
26. Bethke L, Sullivan K, Webb E, Murray A, Schoemaker M, Auvinen A et al CASP8 D302H and meningioma risk: An analysis of five case-control series. Cancer Lett 2009; 273: 312-315.